Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

AMD 2016: A Review of Treatment Guidelines and the Role of Appropriate Therapy

By: Allen C. Ho, MD, moderator; Brandon G. Busbee, MD; Justis P. Ehlers, MD; Darius M. Moshfeghi, MD; John D. Pitcher III, MD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

CONTENT SOURCE
This continuing medical education (CME) activity captures content from a roundtable meeting held in February of 2016 in Vail, Colorado.

TARGET AUDIENCE
This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.

Expiration Date: Monday, July 31, 2017
Release Date: July 1, 2016

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Assess the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF therapies for common retinal diseases, including AMD.
  • Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations.
  • Develop plans to initiate treatment for conditions such as AMD using anti-VEGF agents as well as better understand when to change therapeutic strategies.

Accreditation and Designation Statement

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, New Retina MD, and Retina Today. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC (Evolve) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

Brandon G. Busbee, MD
Tennessee Retina
Nashville, Tennessee

Justis P. Ehlers, MD
Cole Eye Institute
Cleveland, Ohio

Allen C. Ho, MD
Retina Service
Wills Eye Institute
Philadelphia, Pennsylvania

Darius M. Moshfeghi, MD
Stanford University Medical Center
Stanford, California

John D. Pitcher, III, MD
Eye Associates of New Mexico
Albuquerque, New Mexico

DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Brandon G. Busbee, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/Speaker’s Bureau: Aerpio Therapeutics; Genentech, and Valeant Pharmaceuticals International. Grant/Research Support: Aerpio Therapeutics; Genentech; Ohr Pharmaceutical; Opthotech; and Regeneron Pharmaceuticals. Stock/Shareholder: Akorn. Other Financial/Material Support: Akorn.

Justis P. Ehlers, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Bioptigen; Carl Zeiss Meditec; Leica Microsystems; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV. Grant/ Research Support: Genentech; Regeneron Pharmaceuticals, and ThromboGenics NV.

Allen C. Ho, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Advisory Board/Consultant/Speaker’s Bureau: Aerpio Therapeutics; Alcon; Allergan; Beaver-Visitic International; DigiSight Technologies; Endo Optiks; Genentech; Janssen Pharmaceuticals/ Johnson & Johnson; ONL Therapeutics, LLC; Ophthotech; Physician Recommended Nutriceuticals; Regeneron Pharmaceuticals; Regenix; and Second Sight. Grant/Research Support: Alcon; Allergan; Genentech; Janssen Pharmaceuticals/Johnson & Johnson; NEI/NIH; Ophthotech; Physician Recommended Nutriceuticals; Regeneron Pharmaceuticals; and Second Sight.

Darius M. Moshfeghi, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan; and Genentech. Travel: Clarity Medical Systems. Founder/ IP/Equity: InSitu Therapeutics. Steering Committee/Consultant: Iconic

Therapeutics. Consultant/equity: Krypton Vision and Visunex. Founder/Equity: Promisight and Versl.

John D. Pitcher III, MD, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of: Consultant/Advisory Board/Speaker’s Bureau: Allergan.

Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Emily Feinman, administrator, BMC; Michelle Dalton, medical writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, New Retina MD, Retina Today, or Regeneron Pharmaceuticals.

AMD 2016: A Review of Treatment Guidelines and the Role of Appropriate Therapy [SUPPLEMENT]

Allen C. Ho, MD, moderator; Brandon G. Busbee, MD; Justis P. Ehlers, MD; Darius M. Moshfeghi, MD; John D. Pitcher III, MD

BackNext